**Escherichia Coli Bacterin**

**LitterGuard®**

**PRODUCT DESCRIPTION:** LitterGuard is for vaccination of healthy pregnant sows and gilts for passive transfer of protective maternal antibodies to their pigs as an aid in preventing neonatal diarrhea caused by enterotoxigenic strains of *Escherichia coli* having the K99, K88, 987P, or F41 adherence factors. The addition of F41 now offers broader protection than previously available. The bacterin is prepared from chemically inactivated strains of *E. coli*. A sterile adjuvant is used to enhance the immune response.

**DISEASE DESCRIPTION:** Enterotoxigenic strains of *E. coli* are among the most important etiologic agents of peracute neonatal diarrhea. Studies have shown that enterotoxigenic *E. coli* isolated from diarrheic pigs have 2 characteristics in common: (1) they have pilus, surface antigenic structures which attach the bacteria to cells of the intestinal epithelium; and (2) they express enterotoxins, causing the intestinal cells to secrete body fluids and electrolytes into the gut lumen. The results are diarrhea, dehydration, and in severe cases, death. The 4 major pilus types associated with neonatal colibacillosis in swine are K99, K88, 987P, and F41.

**SAFETY AND EFFICACY:** No adverse reactions to LitterGuard were reported in experimental tests, or in clinical trials conducted by independent veterinarians. Anaphylaxis occasionally has been observed in field use (see **PRECAUTIONS**). Susceptible pigs are protected by receiving colostral antibodies from vaccinated dams. Thus, adequate and timely consumption of colostrum by the neonatal pig is essential for protection. Controlled challenge-immunity tests were conducted involving 110 gilts and sows and their litters. Fractions of LitterGuard were tested for effectiveness separately and in combination. Results showed that vaccination of pregnant swine with 2 doses of LitterGuard significantly reduced the incidence and severity of neonatal diarrhea in their litters.

**DIRECTIONS:**

1. Store at 2°–7°C. Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze.
2. Use sterile syringes and needles to administer this vaccine. Do not remove the rubber stopper from the vial until you are ready to inject. Aseptically administer 2 mL intramuscularly or subcutaneously.
3. Primary Vaccination: Healthy pregnant swine should receive 2 doses administered 3 weeks apart during the last half of pregnancy. The second dose should be given at least 2 weeks before farrowing.
4. Revaccination: Pregnant swine should be revaccinated with a single dose at least 2 weeks before each subsequent farrowing.
5. Good animal husbandry and herd health management practices should be employed.

**PRECAUTIONS:**

1. Do not administer within 21 days before slaughter.
2. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.
3. This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.

**REFERENCES:**


Technical inquiries should be directed to Zoetis Inc. Veterinary Services, (888) 963-8471 (USA), (800) 461-0917 (Canada).

For veterinary use only.

KIB component under contract with Cetus Corporation.

U.S. Veterinary License No. 185.

*zqetis*

Zoetis Inc.

Kalamazoo, MI 49007, USA

30351600